Insmed (INSM) Goodwill & Intangibles (2010 - 2026)
Insmed (INSM) posted Goodwill & Intangibles of $229.6 million for Q2 2026, down 0.9% on a QoQ basis from $231.7 million in Q1 2026, and up 68.69% year-over-year from $136.1 million in Q2 2025.
Analysis
Insmed (INSM) Goodwill & Intangibles (2010 - 2026) Analysis & Trends
Insmed has reported Goodwill & Intangibles for 17 years, with the latest figure at $229.6 million in Q2 2026.
- On a quarterly basis, Goodwill & Intangibles rose 68.69% year-over-year to $229.6 million in Q2 2026; TTM through Jun 2026 was $229.6 million, a 68.69% increase from a year earlier, with the FY2025 full-year figure at $233.8 million, up 20.02% from the prior year.
- Goodwill & Intangibles was $229.6 million for Q2 2026 at Insmed, down from $231.7 million in the prior quarter.
- The five-year high for Goodwill & Intangibles was $233.8 million in Q4 2025, with the low at $136.1 million in Q2 2023.
- Average Goodwill & Intangibles over 5 years is $189.6 million, with a median of $201.7 million recorded in 2023.
- The sharpest annual moves came in 2022 and 2023: Goodwill & Intangibles soared 343.76% in 2022, then slumped 34.37% in 2023.
- Over 5 years, Goodwill & Intangibles stood at $204.9 million in 2022, then retreated by 2.47% to $199.8 million in 2023, then decreased by 2.53% to $194.8 million in 2024, then advanced by 20.02% to $233.8 million in 2025, then slipped by 1.78% to $229.6 million in 2026.
- The last three Goodwill & Intangibles figures came in at $229.6 million (Q2 2026), $231.7 million (Q1 2026), and $233.8 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn |
| 10 | BioNTech SE | 26.24 Bn | 12.58 Bn | 10.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 229.60 Mn |
| Mar 31, 2026 | 231.68 Mn |
| Dec 31, 2025 | 233.76 Mn |
| Sep 30, 2025 | 220.70 Mn |
| Jun 30, 2025 | 136.11 Mn |
| Mar 31, 2025 | 193.50 Mn |
| Dec 31, 2024 | 194.76 Mn |
| Sep 30, 2024 | 136.11 Mn |
| Jun 30, 2024 | 136.11 Mn |
| Mar 31, 2024 | 198.55 Mn |
| Dec 31, 2023 | 199.81 Mn |
| Sep 30, 2023 | 136.11 Mn |
| Jun 30, 2023 | 136.11 Mn |
| Mar 31, 2023 | 203.60 Mn |
| Dec 31, 2022 | 204.87 Mn |
| Sep 30, 2022 | 206.13 Mn |
| Jun 30, 2022 | 207.39 Mn |
| Mar 31, 2022 | 208.66 Mn |
| Dec 31, 2021 | 209.92 Mn |
| Sep 30, 2021 | 211.18 Mn |